3D bioprinting is experiencing rapid growth as the technology continues to evolve. This is certainly the case in Australia and AXT, who are already well entrenched in the field are pleased to announce that they are strengthening their position by partnering with CELLINK.
Adicet pauses preclinical programme in CAR-T cell pipeline reprioritisation – Pharmaceutical Technology
Adicet plans to file an investigational new drug (IND) for ADI-270 with the FDA in H1 2024. Image Credit: ART-ur / Shutterstock. Adicet Bio plans